We observed that combination therapy led to a remarkable suppression of tumor growth by ~73% and exhibited a significant improvement in median survival, extending it by 42%, which is superior to that observed with either treatment with anti–PD-1 or TRM-EHs alone (Fig. 6, B and C). The gene discussed is PDCD1; the disease is neoplasm.